详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

ALK Testing in Chinese Advanced NSCLC Patients: A National-Wide Multicenter Prospective Real-World Data Study (The RATICAL Study)

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]National Cancer Center/National Clinical Research Center for Cancer/cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing/CN, [2]The First Affiliated Hospital of Zhengzhou University, Zhengzhou/CN, [3]Fudan University Shanghai Cancer Center, Shanghai/CN, [4]Henan Cancer Hospital, Zhengzhou/CN, [5]The Affiliated First Hospital, School of Medicine, Zhejiang University, Hangzhou/CN, [6]Fourth Hospital of Hebei Medical University, Shjiazhuang/CN, [7]Fujian Cancer Hospital, Fuzhou/ CN, [8]The First Hospital of China Medical University, Shenyang/CN, [9]Zhejiang Cancer Hospital, Hangzhou/CN, [10]Zhongshan Hospital, Fudan University, Shanghai/CN, [11]Beijing Hospital, Beijing/CN, [12]Southwest Hospital, Third Military Medical University, Chongqing/CN, [13]Department of Pathology, Shanghai Chest Hospital, Shanghai/CN, [14]China, China/CN

出处：

DOI：

ISSN：

关键词： Lung cancer Real world data ALK testing

语种：

被引次数：

WOS：

中科院分区：

出版当年[2019]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 2 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2019]版：

Q1 RESPIRATORY SYSTEM Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21.1 最新[2023版] 16.5 最新五年平均 13.357 出版当年[2019版] 10.089 出版当年五年平均 12.46 出版前一年[2018版] 15.609 出版后一年[2020版]

第一作者：

第一作者机构： [1]National Cancer Center/National Clinical Research Center for Cancer/cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing/CN,

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]The Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study [2]Real-world data in clinically non-small cell lung cancer (NSCLC) with Chinese population harboring BRAF gene fusions: A multicenter study. [3]Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China. [4]Real-world data in clinically non-small cell lung cancer (NSCLC) with Chinese population harboring BRAF gene fusions: A multicenter study [5]Real-world data on ALK rearrangement test in Chinese advanced non-small cell lung cancer (RATICAL): a nationwide multicenter retrospective study [6]Real world data on dual BLyS/APRIL inhibition with telitacicept for lupus nephritis [7]Neoadjuvant PD-1 blockade combined with chemotherapy for patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC): A real world data analysis [8]Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancer [9]DEVELOP A REPLICABLE MODEL FOR RATIONAL SELECTION OF STRATEGIES IN TREAT-TO-TARGET AND MAINTAIN-BEING-TARGET: REAL WORLD DATA MINING VIA SMART SYSTEM OF DISEASE MANAGEMENT (SSDM) [10]Real-world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high‑risk breast cancer subgroup patients